7Brater DC. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf, 1996, 14 (2): 104- 120.
8Preston RA, Fernandez L. University of miami division of clinical pharmacology therapeutic rounds: managing hypertension in pa- tients with kidney desease-implications for preservation of renal function. Am J Ther,1998,5(5) :355-362.
6[1]Greger R.Inhibition of active NaCl reabsorption in the thick ascending limb of the loop of Henle by torasemide[J].Arzneimittelforsch,1988,38(1A):151-152.
7[2]Cuvelier R,Pellegrin P,Lesen M,et al.Site of action of torasemide in man[J].Eur J Clin Phamacol,1986,31(Suppl):S15-S19.
8[3]Brater DC.Clinical pharmacology of loop diuretics[J].Drugs,1991,41(Supp 3):S14-S22.
9[4]Knauf H,Mutschler E.Clinical pharmacokinetics and pharmacodynamics of torasemide[J].Clin Pharmacokinet,1998,34(1):1-24.
10[5]Lesne M.Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers[J].Arzneimittelforsch,1988,38(1A):160-163.
